Baihua village to be placed in more than 1 billion 900 million pharmaceutical assets suspension dodg-www.555kfc.com

Baihua village to be placed in more than 1 billion 900 million pharmaceutical assets suspension dodge two wave crash Budie pressure hot column capital flows thousand thousand shares of stock on the latest rating diagnosis simulated trading client Sina Level2:A shares Sina speed Kanpan finance client: the most profitable investors are using baihuacun (600721) announced that the company received on January 26th on the letter of inquiry, intermediary institutions and relevant parties to put forward "reply letter of inquiry by" the problem, and the major asset restructuring plan and the revised. After application, the company’s stock will resume trading on February 16th opening date. According to the plan, baihuacun intends to the original weak profitability of business as set out the assets (at a price of 255 million yuan) and the assets to be placed in Huawei (100% shares at a price of 1 billion 945 million yuan) equivalent replacement part, the difference in part by the company intends to 12.28 yuan of shares of non-public offering of approximately 100 million shares and cash payment of 456 million yuan. At the same time, the company intends to 12.28 yuan shares of non-public offering of shares to raise matching funds of not more than 1 billion 198 million yuan, will be used to pay cash for the price, payment of agency fees, add liquidity and Huawei core projects, which the company ESOP intends to subscribe for not more than 98 million 240 thousand yuan. After the completion of the transaction, the total shareholding of 24.25% shareholders of the Corps, the company’s actual controller is still the six Division of state owned company, the transaction does not constitute backdoor listing. Huawei pharmaceutical drug development for high-end enterprises, for the pharmaceutical industry to provide research, drug discovery, registration and other professional and technical services, has completed several preclinical studies in recent 200, customers include many well-known enterprise groups and listed companies; after the reorganization will achieve the company main business transformation, improve the company’s business situation fundamentally. According to the performance commitment, Huawei medicine from 2016 to 2018 net profit of not less than 100 million yuan, 123 million yuan and 147 million yuan. Baihuacun said, through the reorganization of the original company profitability is weak, uncertain prospects for the future development of the overall business set out at the same time, inject strong profitability, broad prospects for the development of medicine, medical industry assets, restructuring of listed companies to achieve the main business, improve the company’s business situation fundamentally, improve the company’s assets quality, enhance the company’s profitability and the ability of sustainable development. Analysts believe that in July 31st, baihuacun has been suspended, the suspension period, the two wave of A stock market crash, the reorganization of assets due to the limited strength, from a technical point of view, the obvious Budie pressure after the resumption of the stock. Enter Sina Financial shares] discussion

百花村拟置入逾19亿医药资产 停牌躲避两波股灾补跌压力大 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经Level2:A股极速看盘 新浪财经客户端:最赚钱的投资者都在用   百花村(600721)公告称,公司于1月26日收到上交所问询函后,组织中介机构及相关各方对《问询函》中提出的问题进行逐项回复,并对重大资产重组预案及摘要进行了修订。经申请,公司股票将于2月16日开市起恢复交易。   根据方案,百花村拟以原有盈利能力较弱业务作为置出资产(作价2.55亿元)与拟置入资产华威医药100%股份(作价19.45亿元)等值部分进行置换,差额部分由公司拟12.28元 股非公开发行约1亿股及现金4.56亿元支付。   同时公司拟以12.28元 股非公开发行股份募集配套资金不超过11.98亿元,将用于支付现金对价、支付中介机构费用、补充流动资金及华威医药核心项目建设,其中公司员工持股计划拟认购不超过9824万元。此次交易完成后,兵团方股东合计持股比例24.25%,公司实际控制人仍然为六师国资公司,此次交易不构成借壳上市。   华威医药为高端药物研发企业,面向医药行业提供药物发现、研究、注册等专业技术服务,至今已完成近200多项临床前研究,客户群包括众多国内外知名企业集团和上市公司;重组后将实现公司主营业务转型,从根本上改善公司经营状况。根据业绩承诺,华威医药2016年至2018年净利润分别不低于1亿元、1.23亿元和1.47亿元。   百花村表示,通过此次重组,公司将原有盈利能力较弱、未来发展前景不明朗的业务整体置出,同时注入盈利能力较强、发展前景广阔的医药、医疗行业资产,实现上市公司主营业务的转型,从根本上改善公司的经营状况,提高公司的资产质量,增强公司的盈利能力和可持续发展能力。   分析人士认为,百花村于7月31日停牌至今,停牌期间,A股市场发生了两波股灾,由于此次资产重组的力度有限,从技术上看,该股复牌后存在明显的补跌压力。 进入【新浪财经股吧】讨论相关的主题文章: